2019 Press/Media Releases:

OPKO Health Announces Appointment of Patricia Sandler as National Sales Director for Rayaldee

MIAMI, July 16, 2019 (GLOBE NEWSWIRE) -- OPKO Health (NASDAQ: OPK) announced that it has appointed Patricia Sandler as National Sales Director overseeing Rayaldee sales in the United States (U.S.). Ms. Sandler brings over 25 years of sales and marketing experience to OPKO along with a robust track record of success across numerous roles in the pharmaceutical industry. Before joining OPKO, Ms. Sandler most recently served as regional Field Vice President for GlaxoSmithKline. During her career, Ms. Sandler has led multiple product launches, including the first commercial product launch for Omeros Corporation, a Seattle based biotech company. Prior to Omeros, Ms. Sandler served several other prominent pharmaceutical companies, including Sunovion Pharmaceuticals, Inc., Johnson & Johnson and Pfizer, Inc. across a wide range of therapeutic categories, developing a broad skill set pertinent to all stages of brand development.

"We are delighted to welcome Ms. Sandler to our dedicated team of professionals driving Rayaldee sales in the U.S.," stated Dr. Charles W. Bishop, CEO, OPKO Renal Division. "Ms. Sandler has the required experience to further increase the reach and efficiency of our expanding commercial efforts." RAYALDEE is an extended-release prohormone of calcitriol, the active form of vitamin D3. The product is the only such therapy approved by the U.S. Food and Drug Administration (FDA) that raises serum 25-hydroxyvitamin D and lowers blood levels of parathyroid hormone.

RAYALDEE is approved in the U.S. to treat SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency. It is not yet approved for patients with stage 5 CKD on dialysis therapy. OPKO Health launched RAYALDEE in the U.S. in November 2016.

About OPKO Health, Inc.
OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA and testosterone as the most advanced test in development. In our pharmaceutical pipeline, RAYALDEE, to treat secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease and vitamin D insufficiency, is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity recently reported positive data from a Phase 2 clinical trial. It's among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various indications. The Company's most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad. More information is available at www.opko.com.

Contacts:
Investors
LHA Investor Relations
Miriam Weber Miller, 212-838-3777
MMiller@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

 
     
     
 
   

© 2019 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use